Both clinicians emphasized the need to address the child's environment within the context of his or her symptoms, incorporating psychotherapeutic and educational interventions in any treatment strategy. “Medication in the absence of the others [interventions] is rarely successful,” Dr. Chang said.
Dr. Carlson reported that she is a consultant for many of the pharmaceutical companies conducting research into bipolar disorder and ADHD and is currently participating in a study of lamotrigine (GlaxoSmithKline). Dr. Chang said he has received research or grant support from, or served on the speakers bureau for, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly & Co., Otsuka America Pharmaceutical Inc., and GlaxoSmithKline.
By Betsy Bates. Share your thoughts and suggestions at cpnews@elsevier.com
Few data support the use of 'powerful, fat-making antipsychotics' for the rest of the child's life.
Source DR. CARLSON